Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4875166> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q4875166 subject Q7139608.
- Q4875166 subject Q8281844.
- Q4875166 subject Q8546974.
- Q4875166 subject Q8728165.
- Q4875166 subject Q8965786.
- Q4875166 abstract "Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. Bazedoxfiene is the result of an exclusive research collaboration between Wyeth Pharmaceuticals and Ligand Pharmaceuticals. It is approved in the European Union (marketed in Italy and Spain) and Japan, and is in the late phases of review by the United States' Food and Drug Administration (FDA). When approved, bazedoxifene is to be sold by Pfizer under the tradename Viviant in the US, Japan and Conbriza in the EU. Bazedoxifene's combination with conjugated estrogens, Aprela, is undergoing Phase III studies for the treatment of postmenopausal symptoms (including the prevention of postmenopausal osteoporosis/treatment of osteopenia).The drug is being investigated for possible use in dyspareunia (painful sexual intercourse).It is also being studied for possible treatment of breast cancer and pancreatic cancer.".
- Q4875166 atcPrefix "G03".
- Q4875166 atcSuffix "XC02".
- Q4875166 casNumber "198481-32-2".
- Q4875166 drugbank "DB06401".
- Q4875166 fdaUniiCode "Q16TT9C5BK".
- Q4875166 iupacName "1-{4-[2-(Azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol".
- Q4875166 pubchem "154257".
- Q4875166 thumbnail Bazedoxifene.svg?width=300.
- Q4875166 wikiPageWikiLink Q120395.
- Q4875166 wikiPageWikiLink Q130146.
- Q4875166 wikiPageWikiLink Q16274732.
- Q4875166 wikiPageWikiLink Q165328.
- Q4875166 wikiPageWikiLink Q17.
- Q4875166 wikiPageWikiLink Q177708.
- Q4875166 wikiPageWikiLink Q1779868.
- Q4875166 wikiPageWikiLink Q204711.
- Q4875166 wikiPageWikiLink Q206921.
- Q4875166 wikiPageWikiLink Q2198549.
- Q4875166 wikiPageWikiLink Q30612.
- Q4875166 wikiPageWikiLink Q4118295.
- Q4875166 wikiPageWikiLink Q458.
- Q4875166 wikiPageWikiLink Q7139608.
- Q4875166 wikiPageWikiLink Q8281844.
- Q4875166 wikiPageWikiLink Q8546974.
- Q4875166 wikiPageWikiLink Q8728165.
- Q4875166 wikiPageWikiLink Q8965786.
- Q4875166 wikiPageWikiLink Q901932.
- Q4875166 wikiPageWikiLink Q903917.
- Q4875166 atcPrefix "G03".
- Q4875166 atcSuffix "XC02".
- Q4875166 casNumber "198481".
- Q4875166 drugbank "DB06401".
- Q4875166 iupacName "1".
- Q4875166 pubchem "154257".
- Q4875166 unii "Q16TT9C5BK".
- Q4875166 type ChemicalSubstance.
- Q4875166 type Drug.
- Q4875166 type ChemicalObject.
- Q4875166 type Thing.
- Q4875166 type Q8386.
- Q4875166 comment "Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. Bazedoxfiene is the result of an exclusive research collaboration between Wyeth Pharmaceuticals and Ligand Pharmaceuticals.".
- Q4875166 label "Bazedoxifene".
- Q4875166 depiction Bazedoxifene.svg.